Key Takeaways Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.The Swiss ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking The ...

Companies in the US, including Novo Nordisk, Boeing and Shein, are forming task forces to address the impact of Donald ...

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Companies like Novo Nordisk, Boeing, and Walmart are preparing for the impacts of President Donald Trumps tariffs. Executives ...

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...

Record Inventory Increase Meets Growing Consumer Demand for Healthcare Cost-Saving SolutionsSurge Driven by Ozempic and Zepbound Prescription ...

PARIS] Ozempic-maker Novo Nordisk is planning to make more of its medicines for the US market in the country; Boeing risks a ...

The two companies will work together on Zealand’s amylin analogue petrelintide as a monotherapy and in combination therapies.